NCT03484585View on ClinicalTrials.gov

Rogaratinib (BAY1163877) Human Mass Balance Study

PHASE1CompletedINTERVENTIONAL

Enrollment

6

Participants

Timeline

Start Date

April 6, 2018

Primary Completion Date

May 25, 2018

Study Completion Date

August 9, 2018

Conditions

Clinical Trial, Phase IPharmacokinetics

Interventions

DRUG

Rogaratinib (BAY1163877)

Single dose, intake orally, 200 mg

Trial Locations (1)

9728 NZ

PRAHealthSciences, Groningen

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Bayer

INDUSTRY